A randomized surgical window-of-opportunity trial reports that giving dual immune checkpoint blockade before resection increases immune infiltration in recurrent glioblastoma and correlates with extended patient survival. The design uses presurgical therapy to rapidly observe tumor immune remodeling during a defined time window. For glioblastoma, where treatment resistance and immune exclusion remain major obstacles, the study offers clinical evidence that timing and tumor accessibility can meaningfully change the immune microenvironment. The immune infiltration signal provides a measurable pharmacodynamic endpoint for future studies. The data also set up a clearer rationale for neoadjuvant immunotherapy strategies in brain tumors, where post-surgical access and immunosuppressive biology complicate later immune activation.